{"article": [{"url": "https://www.marketwatch.com/story/novavax-starting-trial-of-covid-19-vaccine-in-south-africa-2020-08-17", "published": 1597632380.0, "headline": "Novavax starting trial of COVID-19 vaccine in South Africa", "body": "Novavax NVAX, +0.18% said it's beginning a Phase 2b clinical trial in South Africa to evaluate the efficacy of NVX-CoV2373, its COVID-19 vaccine candidate. The Bill & Melinda Gates Foundation providing $15 million grant toward trial, said Novavax, which last week agreed to sell its vaccine to the U.K. government if successful. \"Because South Africa is experiencing a winter surge of COVID-19 disease, this important Phase 2b clinical trial has the potential to provide an early indication of efficacy, along with additional safety and immunogenicity data for NVX-CoV2373,\" said Gregory Glenn, president of research and development at Novavax."}]}